99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer
British Journal of Radiology · 01.06.2026 · 99 (1182) · 1081-1091
DOI: 10.1093/bjr/tqag052 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 12.03.2026. Verfasst von Monika Hooda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Whole Body Imaging, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals. Die Arbeit nennt 36 Literaturangaben. Gefördert von: DST-SERB.
Abstract (Originalsprache)
Objectives
The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT versus 68Ga-PSMA PET/CT was evaluated in prostate cancer patients.
Methods
As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole-body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole-body imaging was performed at multiple time points of 10 minutes, 2 hours, 4 hours, 6 hours, 24 hours and the whole-body SPECT/CT was acquired at 3 hours. The whole-body SPECT/CT data was analysed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q-Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole-body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.
Results
68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc-HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC-PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; P < .01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.
Conclusions
The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favourable dosimetry indicating its potential for PCa evaluation. Advances in knowledge 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
- Department of Urology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
ORCID-Profile: Baljinder Singh
Förderung
- DST-SERB
Zitieren
APA
Hooda, M., Kaur, K., Watts, A., Singh, H., Kaur, H., Gunasekaran, V., Sharma, A. P., Mavuduru, R., & Singh, B. (2026). 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer. British Journal of Radiology, 99(1182), 1081-1091. https://doi.org/10.1093/bjr/tqag052
Vancouver
Hooda M, Kaur K, Watts A, Singh H, Kaur H, Gunasekaran V, et al. 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer. British Journal of Radiology. 2026;99(1182):1081-1091. doi:10.1093/bjr/tqag052
BibTeX
@article{Hooda2026,
author = {Hooda, Monika and Kaur, Komalpreet and Watts, Ankit and Singh, Harmandeep and Kaur, Harneet and Gunasekaran, Vinisha and Sharma, Aditya P and Mavuduru, Ravimohan and Singh, Baljinder},
title = {99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer},
journal = {British Journal of Radiology},
year = {2026},
volume = {99},
number = {1182},
pages = {1081--1091},
doi = {10.1093/bjr/tqag052}
}
EUVIMED